Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $3.2 million.

  • Assembly Biosciences' Non-Current Assets rose 55.44% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 55.44%. This contributed to the annual value of $3.7 million for FY2024, which is 20.72% up from last year.
  • Latest data reveals that Assembly Biosciences reported Non-Current Assets of $3.2 million as of Q3 2025, which was down 3.86% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Non-Current Assets registered a high of $60.8 million during Q3 2021, and its lowest value of $2.0 million during Q3 2023.
  • In the last 3 years, Assembly Biosciences' Non-Current Assets had a median value of $3.0 million in 2023 and averaged $2.9 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 89.45% in 2023, then spiked by 55.44% in 2025.
  • Quarterly analysis of 5 years shows Assembly Biosciences' Non-Current Assets stood at $36.9 million in 2021, then tumbled by 86.90% to $4.8 million in 2022, then plummeted by 37.10% to $3.0 million in 2023, then grew by 20.72% to $3.7 million in 2024, then surged by 55.44% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.3 million for Q2 2025, and $3.5 million during Q1 2025.